EnWave Strengthens Board With New Independent Director, Grants Options

EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave" or "the Company"),
an industrial technology company commercializing a new high-speed method of
dehydration for food, bulk liquids and pharmaceuticals, today announced that it
has appointed Mr. J. Hugh Wiebe as a Non-Executive Independent Director to the
Company's Board. Mr. Wiebe is an entrepreneur with a long history of company
development in the areas of live and active biomaterials and food products. He
is the founder of international egg producer Brookside Farms, Ltd., chocolate
producer Brookside Foods, Ltd., and enzyme producer NeovaTech Inc., now a
subsidiary of Bioseutica PLC.


Mr. Wiebe was an early pioneer in the development of enzymes for a variety of
food applications, and has developed international operations and customer
relationships for these products in Europe, Japan and North America. He also has
extensive experience with both spray drying and freeze drying technologies as
they are used to preserve food and biomaterials. Mr. Wiebe is currently the
Chairman of the Board of Brookside Foods, Ltd., the President and CEO of Bioplex
Nutrition Inc., and serves as a Board member for a number of companies operating
in the biomaterials sector, including Bioseutica PLC.


"I have known Hugh for many years and anticipate that his industry knowledge and
experience will help EnWave speed the introduction of our Radiant Energy Vacuum
dehydration technologies into the biomaterials and food markets," said Dr. Tim
Durance, EnWave's Chairman and Co-CEO. "In addition, his independent direction
will also help us in our continual bid to deliver top notch corporate governance
and operations oversight."


The Company has also granted 425,000 stock options to its Directors and Officers
pursuant to its Share Option Plan (the "Plan"). Each option will entitle its
holder to purchase one common share of the Company at an exercise price of $1.70
per share for a period of five years from this date. The options will vest in
accordance to provisions set out in the Plan, or as otherwise required by the
TSX Venture Exchange. The grant is subject to regulatory approval.


About EnWave

Using proprietary technologies developed in conjunction with the University of
British Columbia, EnWave is commercializing a new method for dehydrating food
and biological materials using Radiant Energy Vacuum ("REV") technology under
its nutraREV(TM), powderREV(TM), bioREV(TM) and freezeREV(TM) brands. REV
technology combines microwave energy transfer under vacuum to dehydrate and
alter structures and drive chemical reactions, thereby creating unique product
characteristics for both food products and medical applications that include
fruit, vegetables, probiotics, enzymes, proteins, food cultures, vaccines and
antibodies. More information about EnWave is available at www.enwave.net. 


EnWave Corporation

Dr. Tim Durance, Chairman & Co-CEO

Safe Harbour for Forward-Looking Information Statements: This press release may
contain forward-looking information based on management's expectations,
estimates and projections. All statements that address expectations or
projections about the future, including statements about the Company's strategy
for growth, product development, market position, expected expenditures and
financial results are forward-looking statements. These statements are not a
guarantee of future performance and involve a number of risks, uncertainties and
assumptions. There is no guarantee that transactions contemplated under the
agreements for the acquisition of the Intellectual Property will close, there is
no guarantee the Company's REV technology can or will improve processes in the
target industry; even if the Company's REV technology can be used as described
in this document, there is no guarantee that such use will result in orders for
the Company's REV technology. All figures comparing REV technologies to freeze
drying or other dehydration technologies are provided as examples of data
obtained through the Company's own scientific and testing programs; each product
must be tested individually to determine the benefits of using REV.
(TSXV:REV)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024